Expansion of antibacterial spectrum of muraymycins toward pseudomonas aeruginosa

ACS Medicinal Chemistry Letters

Volumn 5, Issue 5, 2014, Pages 556-560

  Takeoka, Yusuke ^a   Tanino, Tetsuya ^b   Sekiguchi, Mitsuaki ^a   Yonezawa, Shuji ^a   Sakagami, Masahiro ^a   Takahashi, Fumiyo ^a   Togame, Hiroko ^a   Tanaka, Yoshikazu ^a   Takemoto, Hiroshi ^a   Ichikawa, Satoshi ^b   Matsuda, Akira ^b  

^a SHIONOGI AND CO LTD   (Japan)

^b HOKKAIDO UNIVERSITY   (Japan)

Author keywords

anti Pseudomonas; Antibiotics; drug resistance; MraY; muraymycin; peptidoglycan

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; FUNCTIONAL GROUP; MURAYMYCIN; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL STRAIN; BIOLOGICAL ACTIVITY; DRUG SCREENING; HUMAN; IC 50; LIPOPHILICITY; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; RAT; STRUCTURE ACTIVITY RELATION;

EID: 84900458326     PISSN: None     EISSN: 19485875     Source Type: Journal    
DOI: 10.1021/ml5000096     Document Type: Article

References (24)

1. Tam, V. H.; Chang, K. T.; Abdelraouf, K.; Brioso, C. G.; Ameka, M.; McCaskey, L. A.; Weston, J. S.; Caeiro, J. P.; Garey, K. W. Prevalence, resistance mechanisms, and susceptibility of multidrug-resistant bloodstream isolates of Pseudomonas aeruginosa Antimicrob. Agents Chemother. 2010, 54, 1160-1164
2. Page, M. G.; Heim, J. Prospects for the next anti-Pseudomonas drug Curr. Opin. Pharmacol. 2009, 9, 558-565
3. Scheld, M.; Spellberg, B.; Bartlett, J. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America Clin. Infect. Dis. 2009, 48, 1-12
4. Payne, D. J.; Gwynn, M. N.; Holms, D. J.; Pompliano, D. L. Drugs for bad bugs: confronting the challenges of antibacterial discovery Nat. Rev. Drug Discovery 2007, 6, 29-40
5. Talbot, G. H.; Bradley, J.; Edwards, J. E., Jr.; Gilbert, D.; Scheld, M.; Bartlett, J. G. Bad bugs need drugs: an update on the development pipeline from the antimicrobial availability task force of the Infectious Diseases Society of America Clin. Infect. Dis. 2006, 42, 657-668
6. Overbye, K. M.; Barrett, J. F. Antibiotics: where did we go wrong? Drug Discovery Today 2005, 10, 45-52
7. Monagham, R. L.; Barrett, J. F. Antibacterial drug discovery-then, now and the genomics future Biochem. Pharmacol. 2006, 71, 901-909
8. Walsh, C. Where will new antibiotics come from? Nat. Rev. Microbiol. 2003, 1, 65-70
9. McDonald, L. A.; Barbieri, L. R.; Carter, G. T.; Lenoy, E.; Lotvin, J.; Petersen, P. J.; Siegel, M. M.; Singh, G.; Williamson, R. T. Structures of the muraymycins, novel peptidoglycan biosynthesis inhibitors J. Am. Chem. Soc. 2002, 124, 10260-10261
10. Carter, G. T.; Lotvin, J. A.; McDonald, L. A. WO 2002085310 A2.
11. Winn, M.; Goss, R. J. M.; Kimura, K.; Bugg, T. D. H. Antimicrobial nucleoside antibiotics targeting cell wall assembly: Recent advances in structure-function studies and nucleoside biosynthesis Nat. Prod. Rep. 2010, 27, 279-304
12. Bugg, T. D. H.; Lloyd, A. J.; Roper, D. I. Phospho-MurNAc-pentapeptide translocase (MraY) as a target for antibacterial agents and antibacterial proteins Infect. Dis. Drug Targets 2006, 6, 85-106
13. Kimura, K.; Bugg, T. D. H. Recent advances in antimicrobial nucleoside antibiotics targeting cell wall biosynthesis Nat. Prod. Rep. 2003, 20, 252-273
14. Bouhss, A.; Mengin-Lecreulx, D.; Le Beller, D.; Van Heijenoort, J. Topological analysis of the MraY protein catalyzing the first membrane step of peptidoglycan synthesis Mol. Microbiol. 1999, 34, 576-585
15. Bouhss, A.; Trunkfield, A. E.; Bugg, T. D.; Mengin-Lecreulx, D. The biosynthesis of peptidoglycan lipid-linked intermediates FEMS Microbiol. Rev. 2008, 32, 208-33
16. Al-Dabbagh, B.; Henry, X.; El Ghachi, M.; Auger, G.; Blanot, D.; Parquet, C.; Mengin-Lecreulx, D.; Bouhss, A. Active site mapping of MraY, a member of the polyprenyl-phosphate N -acetylhexosamine 1-phosphate transferase superfamily, catalyzing the first membrane step of peptidoglycan biosynthesis Biochemistry 2008, 47, 8919-8928
17. Tanino, T.; Ichikawa, S.; Shiro, M.; Matsuda, A. Total synthesis of (-)-muraymycin D2 and its epimer J. Org. Chem. 2010, 75, 1366-1377
18. Tanino, T.; Ichikawa, S.; Al-Dabbagh, B.; Bouhss, A.; Matsuda, A. Synthesis and biological evaluation of muraymycin analogues as potential anti-drug-resistant bacterial ACS Med. Chem. Lett. 2010, 1, 258-262
19. Tanino, T.; Al-Dabbagh, B.; Mengin-Lecreulx, D.; Bouhss, A.; Oyama, H.; Ichikawa, S.; Matsuda, A. Mechanistic analysis of muraymycin analogues: a guide to the design of MraY inhibitors J. Med. Chem. 2011, 54, 8421-8439
20. Bouhss, A.; Crouvoisier, M.; Blanot, D.; Mengin-Lecreulx, D. Purification and characterization of the bacterial MraY translocase catalyzing the first membrane step of peptidoglycan biosynthesis J. Biol. Chem. 2004, 279, 29974
21. Stachyra, T.; Dini, C.; Ferrari, P.; Bouhss, A.; van Heijenoort, J.; Mengin-Lecreulx, D.; Blanot, D.; Biton, J.; Le Beller, D. Fluorescence detection-based functional assay for high-throughput screening for MraY Antimicrob. Agents Chemother. 2004, 48, 897-902
22. 3, inhibitors of peptidoglycan synthesis in methicillin-resistant Staphylococcus aureus Antimicrob. Agents Chemother. 2001, 45, 1823-1827
23. Hirano, S.; Ichikawa, S.; Matsuda, A. Total synthesis of caprazol, a core structure of the caprazamycin antituberculosis antibiotics Angew. Chem., Int. Ed. 2005, 44, 1854-1856
24. Hirano, S.; Ichikawa, S.; Matsuda, A. Development of a highly β-selective ribosylation reaction without using neighboring group participation: total synthesis of (+)-caprazol, a core structure of caprazamycins J. Org. Chem. 2007, 72, 9936-9946